Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,203 trials

NCT05653622
Recruiting
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
Phase 2 · France · 3 sites
Registry update: 4 Feb 2026
NCT06905925
Recruiting
The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy
Not applicable · 1 site
Registry update: 12 Sept 2025
NCT07003074
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Phase 3 · China · 23 sites
Registry update: 25 Jun 2025
NCT06696768
Recruiting
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Phase 1 · United States · 13 sites
Registry update: 9 Sept 2026
NCT07085559
Recruiting
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Early phase 1 · China · 1 site
Registry update: 25 Jul 2025
NCT06946199
Recruiting
An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
Phase 1 · China · 1 site
Registry update: 12 Jan 2026
NCT06516640
Recruiting
Type 2 Continuous Glucose Monitoring Academy
Not applicable · United States · 1 site
Registry update: 6 Feb 2026
NCT06926244
Recruiting
RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Not applicable · France · 1 site
Registry update: 23 Jun 2026
NCT07215390
Recruiting
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Phase 2 · United States · 78 sites
Registry update: 24 Jun 2026
NCT06938282
Recruiting
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
Phase 2 · China · 1 site
Registry update: 26 Aug 2026
NCT06961214
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Phase 3 · Argentina, Austria, Australia, Bulgaria, Czechia, Germany, United Kingdom, Greece, Israel, Italy, South Korea, Latvia, New Zealand, Romania, Thailand, United States · 174 sites
Registry update: 5 Oct 2026
NCT06464926
Recruiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
Not applicable · Belgium, France, United Kingdom, Sweden, United States · 22 sites
Registry update: 14 May 2026
NCT06846281
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, Switzerland, Czechia, Germany, Denmark, Spain, France, United Kingdom, Greece, Italy, Mexico, Portugal, Slovakia, United States, South Africa · 132 sites
Registry update: 26 Oct 2026
NCT07043387
Recruiting
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
Not applicable · South Korea · 4 sites
Registry update: 18 Aug 2026
NCT07022704
Recruiting
Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial
Not applicable · Egypt · 1 site
Registry update: 26 Jun 2025
NCT06862219
Recruiting
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Phase 4 · India · 15 sites
Registry update: 21 Aug 2026
NCT06926140
Recruiting
Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
Not applicable · China · 3 sites
Registry update: 24 Jul 2025
NCT07012980
Recruiting
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Phase 2 · China · 1 site
Registry update: 16 Oct 2026
NCT07427992
Recruiting
Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma
Not applicable · Italy · 1 site
Registry update: 23 Feb 2026
NCT06980272
Recruiting
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
Phase 3 · China · 1 site
Registry update: 24 Jun 2025

Ordered by registry start date. Freshness and sponsorship never change the order.